Project Grant R01CA274541

Award Date 7/1/24
Completion Date 6/30/28
Dollars Obligated $403K
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
This Project Grant award of $357,694 from the National Cancer Institute (CFDA Program 93.393 - Cancer Cause and Prevention Research) aims to conduct research on health insurance disparities and their impact on cancer outcomes. The project, titled "Health Insurance and Disparities: More Than Access," will build on an established linkage between the Colorado Central Cancer Registry and the Colorado All-Payer Claims Database to analyze the role of plan type, patient demographics,...
This Project Grant award of $708,091 from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), supports the development and testing of the Algorithm-Enabled Patients Activated in Cancer Care through Teams (A-PACT) intervention. A-PACT uses machine learning algorithms to automatically identify high-risk cancer patients who require urgent goals of care conversations, and then engages these patients through a six-month telephonic intervention...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $192,489 to the University of Alabama at Birmingham (UAB) from February 1, 2025 to January 31, 2030. The project aims to evaluate the implementation and impact of oncology financial navigation, an evidence-based intervention to help cancer patients manage treatment-related financial hardship. Key activities include: Tracking implementation strategies and their effect on outcomes like...
This federal Project Grant award of $334,233, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, will support a comprehensive research study examining disparities in novel cancer therapies, the joint effects of cancer treatment and comorbidities, and multi-level contributors to cancer survival outcomes. The University of South Carolina, the prime awardee, will conduct innovative data linkages between the state cancer registry,...
This Project Grant award of $589,591 from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) supports a study to determine barriers leading to inferior survival for Black and Hispanic patients with Hodgkin lymphoma. The key products/services to be delivered include: Examining differences in the receipt and quality of Hodgkin lymphoma treatment for initial diagnosis and relapse, particularly for patients who have relapsed....
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support a $1,338,648 hybrid effectiveness-implementation trial of the CARES intervention at the University of Pittsburgh. CARES is an integrated electronic health record-based screening and stepped collaborative care program designed to improve patient-centered outcomes for over 18 million Americans living with cancer who experience clinically significant levels of depression,...
This $215,546 Project Grant was awarded by the National Institute on Minority Health and Health Disparities (NIMHD), part of the National Institutes of Health (NIH), under the Minority Health and Health Disparities Research (CFDA 93.307) program. The project aims to evaluate the equity impact and cost-effectiveness of three real-world lung cancer screening strategies: the U.S. Preventive Services Task Force (USPSTF) guidelines, the American Cancer Society (ACS) guidelines, and a screening...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $968,999 to the University of North Carolina at Chapel Hill to conduct a research study titled "OPTIMIZING SURVEILLANCE IN LUNG CANCER SURVIVORS WITH NOVEL IMAGING BIOMARKERS AND DEEP-LEARNING (OPTIMAL)". The goal of the study is to optimize post-treatment surveillance and monitoring of early-stage non-small cell lung cancer survivors by leveraging routine...
This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $478,977 to the Morehouse School of Medicine to conduct a retrospective cohort study on racial disparities in lung cancer treatment and survival. The key objectives are to: Determine racial disparities in the receipt of cancer treatments, time to first treatment, number of treatment cycles, and dosage for non-small cell lung cancer (NSCLC) patients. Assess the...
This $2,372,456 Project Grant awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support a collaborative research program led by Memorial Sloan Kettering Cancer Center focused on leveraging observational (real-world) data to advance precision oncology. The key products and services to be delivered include: Overcoming methodological barriers in the analysis of observational clinico-genomic data (Project 1) Addressing the role of genetic ancestry...

DISPARITIES IN FINANCIAL AND CLINICAL OUTCOMES AMONG COMMERCIALLY-INSURED CANCER PATIENTS FOLLOWING THE AFFORDABLE CARE ACT - PROJECT SUMMARY/ABSTRACT DEMOGRAPHIC CHANGES IN THE COMMERCIALLY INSURED POPULATION FOLLOWING IMPLEMENTATION OF THE AFFORDABLE CARE ACT (ACA)-SPECIFICALLY IMPROVED ENROLLMENT OF THE NEAR-POOR AND THOSE WITH CHRONIC COMORBIDITIES--MAY HAVE PARADOXICALLY MAGNIFIED THE PROBLEM OF "UNDERINSURANCE;" THAT IS, INSURANCE THAT LEAVES PERSONS AT HIGH RISK FOR FINANCIAL HARDSHIP AND CARE GAPS FOLLOWING ILLNESS. THE CENTRAL OBJECTIVE FOR THIS STUDY IS TO UNDERSTAND THE EXTENT TO WHICH COMMERCIALLY INSURED CANCER PATIENTS--PARTICULARLY THE NEAR-POOR AND THOSE WITH CHRONIC CONDITIONS-ARE AT RISK FOR SHORTFALLS IN CARE AND ADVERSE FINANCIAL OUTCOMES. OUR WORKING HYPOTHESIS IS THAT UNDERINSURANCE IS CAUSING GAPS IN CARE AND FINANCIAL HARDSHIP FOR A SUBSTANTIAL PROPORTION OF VULNERABLE CANCER PATIENTS WITH COMMERCIAL INSURANCE IN THE POST-ACA ERA. TO ADDRESS OUR OBJECTIVE AND HYPOTHESIS, WE WILL UTILIZE A NOVEL PERSON-LINKED, POPULATION-LEVEL DATABASE THAT INCLUDES: 1) WESTERN WA SEER CANCER REGISTRY DATA FOR CANCER PATIENTS DIAGNOSED IN 2009-2022; 2) WA STATE VOTER REGISTRATION FILE DATA (NON-CANCER CONTROLS); 3) ENROLLMENT AND CLAIMS RECORDS FROM THE STATE'S LARGEST COMMERCIAL PAYERS (REGENCE BLUE SHIELD AND PREMERA BLUE CROSS); 4) LONGITUDINAL FINANCIAL AND CREDIT RECORDS FROM TRANSUNION; 5) WASHINGTON STATE BANKRUPTCY RECORDS AND 6) MEDICAID ENROLLMENT RECORDS. USING THIS UNIQUE DATABASE THAT IS UPDATED ANNUALLY, OUR FIRST AIM IS TO UNDERSTAND HOW THE NEIGHBORHOOD CHARACTERISTICS, FINANCIAL HEALTH, AND CLINICAL CHARACTERISTICS OF COMMERCIALLY INSURED CANCER PATIENTS HAVE CHANGED FOLLOWING ACA IMPLEMENTATION. DUE TO EXPANDED ELIGIBILITY FOR COMMERCIAL INSURANCE UNDER THE ACA, WE HYPOTHESIZE THAT A GREATER PROPORTION OF CANCER PATIENTS DIAGNOSED POST-ACA (2015-2022) LIVE IN SOCIOECONOMICALLY DISADVANTAGED NEIGHBORHOODS, ARE FINANCIALLY FRAGILE (LOWER CREDIT, HIGHER DEBT, DELINQUENT PAYMENTS), AND HAVE MORE COMORBIDITIES THAN PRE-ACA (2009- 2012) PATIENTS. OUR SECOND AIM IS TO ESTIMATE POST-ACA TRENDS IN OUT-OF-POCKET (OOP) COST EXPOSURE AND UNDERINSURANCE, WITH EMPHASIS ON VULNERABLE POPULATIONS. WE WILL CHARACTERIZE TRENDS AND VARIABILITY IN OOP EXPOSURE AND RISK OF UNDERINSURANCE FOR CANCER PATIENTS ACROSS EMPLOYER-BASED AND ACA MARKETPLACE PLANS. OUR THIRD AIM IS TO DETERMINE THE EXTENT TO WHICH COMMERCIALLY INSURED, VULNERABLE CANCER PATIENTS DIAGNOSED AFTER IMPLEMENTATION OF THE ACA EXPERIENCE DISPARITIES IN CARE AND OUTCOMES COMPARED TO LESS VULNERABLE PATIENTS. IN ADDITION, WE WILL MEASURE THE RELATIONSHIP BETWEEN OOP COST EXPOSURE AND ADVERSE OUTCOMES FOR EACH POPULATION, DEFINED AS GAPS IN QUALITY OF CARE, FINANCIAL HARDSHIP, AND DISENROLLMENT FROM COMMERCIAL INSURANCE AND/OR ENROLLMENT IN MEDICAID FOLLOWING DIAGNOSIS. THIS UNIQUE STUDY AND ONGOING COLLABORATION WITH AN EXTERNAL, COMMUNITY-BASED MULTI-STAKEHOLDER ADVISORY GROUP WILL PROVIDE CRUCIAL EVIDENCE TO INFORM CLINICAL AND POLICY DISCUSSIONS AIMED AT IDENTIFYING AND REDUCING DISPARITIES IN TREATMENT AND OUTCOMES AMONG COMMERCIALLY INSURED CANCER PATIENTS IN THE POST-ACA ERA.

Posted 6/14/24, 12:00 AM